Kiora Pharmaceuticals (KPRX) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiora Pharmaceuticals (KPRX) has outperformed Lantern Pharma (LTRN) over the past year, losing 7.3% versus a loss of 81.9%. Over five years, LTRN leads with a -91.7% price change compared with -99.6% for KPRX. Lantern Pharma is the larger company by market cap ($12.1 million vs $11.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPRX | LTRN |
|---|---|---|
| Share price | $2.54 | $0.8127 |
| Market cap | $11.24M | $12.14M |
| 1-day change | +0.40% | -2.08% |
| YTD return | +28.43% | -72.61% |
| 1-year return | -7.33% | -81.92% |
| 5-year return | -99.64% | -91.71% |
| EPS (TTM) | $-2.46 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.91 | $4.68 |
| 52-week low | $1.77 | $0.7603 |
| Distance from 52-week high | -12.71% | -82.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +372.44% | +2053.32% |
| Average volume | 17.41K | 180.42K |
| Shares outstanding | 4.42M | 14.94M |
| Employees | 13 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KPRX has outperformed LTRN by 74.6 percentage points over the past year.
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
KPRX vs LTRN FAQ
Which is bigger, Kiora Pharmaceuticals or Lantern Pharma?
Lantern Pharma (LTRN) is larger, with a market capitalization of $12.14M compared with $11.24M for Kiora Pharmaceuticals (KPRX).
Which stock has performed better over the past year, KPRX or LTRN?
KPRX returned -7.33% over the past 12 months, compared with -81.92% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are Kiora Pharmaceuticals and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.